NCX 470 Shows Superior IOP Control Over Latanoprost in Mont Blanc Trial Analysis
Key Insights
New analysis from Mont Blanc Phase 3 trial reveals NCX 470 enabled more patients to achieve target intraocular pressure (search) of ≤18 mmHg compared to standard-of-care latanoprost.
NCX 470 demonstrated consistent IOP-lowering effects regardless of baseline pressure, with a significantly higher proportion of patients achieving >10 mmHg reduction versus latanoprost.
Nicox remains on track for U.S. New Drug Application submission in H1 2026, with Denali Phase 3 trial results expected in Q3 2025.
Nicox's novel glaucoma (search) treatment NCX 470 has demonstrated superior intraocular pressure (search) (IOP) control compared to the current standard of care, according to new analysis presented at the 2025 American Glaucoma Society Annual Meeting in Washington.
The latest analysis from the Mont Blanc Phase 3 clinical trial showed that a statistically significant greater proportion of patients treated with NCX 470 0.1% achieved mean diurnal IOP levels of ≤18 mmHg compared to those receiving latanoprost 0.005%. The findings represent a crucial advancement in glaucoma (search) treatment options.
"These data provide another example of where NCX 470 is differentiated from the standard-of-care for intraocular pressure (search) reduction, latanoprost," stated Doug Hubatsch, Chief Scientific Officer of Nicox. "In this analysis, we demonstrated that more patients achieve intraocular pressure of less than or equal to 18 mmHg on NCX 470 than on latanoprost."
Key Efficacy Findings
The post-hoc analysis revealed several significant advantages of NCX 470:
- Greater mean percentage reduction in IOP compared to latanoprost
- Consistent IOP-lowering effect regardless of baseline pressure
- Statistically significant superior IOP reduction in eyes with initial IOP ≤28 mmHg
- Higher proportion of patients achieving >10 mmHg reduction from baseline
The Mont Blanc trial previously demonstrated NCX 470's non-inferiority to latanoprost, achieving IOP reductions of 8.0 to 9.7 mmHg. While the drug did not meet statistical superiority in pre-specified secondary analyses, it showed numerical superiority at all timepoints and statistical significance at 4 of 6 measurements (p<0.049).
Development Timeline and Next Steps
Nicox is advancing multiple clinical programs to support regulatory submissions:
- The Whistler Phase 3b trial, investigating NCX 470's dual mechanism of action, expects results by mid-Q2 2025
- The pivotal Denali Phase 3 trial remains on schedule with topline results anticipated in Q3 2025
- U.S. New Drug Application submission is targeted for H1 2026, supporting potential market launch in H1 2027
The company is currently pursuing partnership opportunities for the U.S. market while continuing development activities in China through its partnership with Ocumension Therapeutics (search). These activities include ongoing clinical trials, non-clinical studies, and pharmaceutical development work necessary for regulatory submission.